RAZADYNE Drug Patent Profile

Which patents cover Razadyne, and what generic alternatives are available?

Razadyne is a drug marketed by Janssen Pharms and is included in three NDAs.

The generic ingredient in RAZADYNE is galantamine hydrobromide. There are fifteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the galantamine hydrobromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Razadyne

A generic version of RAZADYNE was approved as galantamine hydrobromide by BARR on August 28^th, 2008.

Summary for RAZADYNE

US Patents:	0
Applicants:	1
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	160
Clinical Trials:	21
Patent Applications:	880
Drug Prices:	Drug price information for RAZADYNE
What excipients (inactive ingredients) are in RAZADYNE?	RAZADYNE excipients list
DailyMed Link:	RAZADYNE at DailyMed

See drug prices for RAZADYNE

Recent Clinical Trials for RAZADYNE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vanderbilt University Medical Center	Phase 1
Doris Duke Charitable Foundation	Phase 1/Phase 2
Vanderbilt University Medical Center	Phase 1/Phase 2

See all RAZADYNE clinical trials

Paragraph IV (Patent) Challenges for RAZADYNE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RAZADYNE	Tablets	galantamine hydrobromide	4 mg, 8 mg and 12 mg	021169	14	2005-02-28

US Patents and Regulatory Information for RAZADYNE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	RAZADYNE	galantamine hydrobromide	SOLUTION;ORAL	021224-001	Jun 22, 2001		DISCN	No	No
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-003	Apr 1, 2005		DISCN	Yes	No
Janssen Pharms	RAZADYNE	galantamine hydrobromide	TABLET;ORAL	021169-003	Feb 28, 2001		DISCN	Yes	No
Janssen Pharms	RAZADYNE	galantamine hydrobromide	TABLET;ORAL	021169-001	Feb 28, 2001		DISCN	Yes	No
Janssen Pharms	RAZADYNE	galantamine hydrobromide	TABLET;ORAL	021169-002	Feb 28, 2001		DISCN	Yes	No

Expired US Patents for RAZADYNE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	RAZADYNE	galantamine hydrobromide	SOLUTION;ORAL	021224-001	Jun 22, 2001
Janssen Pharms	RAZADYNE	galantamine hydrobromide	TABLET;ORAL	021169-003	Feb 28, 2001
Janssen Pharms	RAZADYNE	galantamine hydrobromide	TABLET;ORAL	021169-002	Feb 28, 2001
Janssen Pharms	RAZADYNE	galantamine hydrobromide	TABLET;ORAL	021169-003	Feb 28, 2001
Janssen Pharms	RAZADYNE	galantamine hydrobromide	TABLET;ORAL	021169-003	Feb 28, 2001

International Patents for RAZADYNE

See the table below for patents covering RAZADYNE around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2257431	COMPRIME DE BROMHYDRATE DE GALANTHAMINE A DISSOLUTION RAPIDE (FAST-DISSOLVING GALANTHAMINE HYDROBROMIDE TABLET)
Spain	2235234
China	1222077
Australia	3174397
Luxembourg	90710

Supplementary Protection Certificates for RAZADYNE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0236684	C00236684/01	Switzerland		FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0236684	C300140	Netherlands		PRODUCT NAME: GALANTAMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER GALANTAMINE HYDROBROMIDE; NAT. REGISTRATION NO/DATE: RVG 29073 - RVG 29076 20030702; FIRST REGISTRATION: SE 15561 - 15565 20000225
0236684	3/2001	Austria		PRODUCT NAME: GALANTAMIN ODER SAEUREADDITIONSSALZE DAVON; NAT. REGISTRATION NO/DATE: 1-23748, 1-23749, 1-23750, 1-23751 20000822; FIRST REGISTRATION: SE 15561, 15562, 15563,15565 20000301
0236684	SPC/GB00/033	United Kingdom		PRODUCT NAME: GALANTHAMINE OR ACID ADDITION SALTS THEREOF; REGISTERED: SE 15561 20000301; SE 15562 20000301; SE 15563 20000301; SE 15565 20000301; UK PL08557/0039 20000914; UK PL08557/0040 20000914; UK PL08557/0041 20000914; UK PL08557/0042 20000914
0236684	2001C/007	Belgium		PRODUCT NAME: GALANTAMINUM HYDROBROMIDUM; NAT. REGISTRATION NO/DATE: 1028 IS 94 F3 20000918; FIRST REGISTRATION: SE 15561 20000301

RAZADYNE Market Analysis and Financial Projection

Last updated: February 16, 2026

What Are the Market Dynamics for RAZADYNE?

Razadyne (galantamine) is approved for the symptomatic treatment of mild to moderate Alzheimer's disease. It is marketed primarily in the United States and Europe. Its market landscape is influenced by competitive drugs, R&D pipelines, regulatory decisions, and demographic trends.

Competitive Landscape

• Razadyne faces competition from other cholinesterase inhibitors such as donepezil (Aricept), rivastigmine (Exelon), and memantine (Namenda).
• These competitors often dominate sales due to higher brand recognition and wider physician adoption.
• The emergence of combination therapies and the development of novel treatments targeting amyloid beta plaques and tau proteins threaten the market share of traditional cholinesterase inhibitors.

Regulatory and Approval Trends

• Razadyne was approved by the FDA in 2001.
• Its approvals in other regions are synchronized with changes in prescribing guidelines.
• The drug’s patent expired in 2011, leading to increased generic competition, which reduced market revenue.
• No recent major regulatory decisions have bolstered or diminished Razadyne’s market presence significantly beyond generic entry.

Demographic and Epidemiological Factors

• The population aged 65+ is increasing globally, with projections to reach 1.5 billion by 2050.
• Alzheimer's disease prevalence in this group is approximately 6-8%, creating a growing base of potential patients.
• Market growth is constrained by the limited efficacy of current treatments and the high unmet need for disease-modifying therapies.

Market Size and Growth

• Based on IQVIA data, the global Alzheimer's drug market was valued at around $9 billion in 2022.
• Razadyne's contribution has declined from peak sales of approximately $500 million in 2004–2005 to less than $50 million annually since patent loss.
• The generics segment dominates the market, with low barriers to entry and price erosion.

What Is the Financial Trajectory for Razadyne?

Market revenues for Razadyne mainly stem from branded and generic sales. The patent expiration led to a sharp decline, and current revenues reflect a declining, generic-dominated market.

Revenue Trends

• Peak revenues (~2004–2005): ~$500 million globally.
• Post-patent expiration (2011): Revenue drops by over 80%.
• Current revenues: Less than $10 million annually, predominantly from generic sales.

Cost Structure and Profitability

• Original manufacturing costs are low; however, branded formulations involve R&D, marketing, and regulatory expenses.
• With patent expiry, profit margins decline sharply due to generic competition, which drives prices down by as much as 80%.

R&D and Market Investment

• No recent clinical development programs for Razadyne are publicly disclosed.
• Investment from the original patent holder, Janssen (a Johnson & Johnson subsidiary), was primarily in patent filing and compliance.
• The focus has shifted to pipeline drugs targeting disease modification rather than symptomatic treatments like Razadyne.

Future Outlook

• The outlook for Razadyne’s financial performance is bleak absent new indications or formulations.
• The rise of generics means minimal revenue potential unless a new formulation or combination therapy is introduced.
• Continued decline of branded sales is expected, consistent with typical lifecycle patterns post-patent expiry.

Summary of Key Financial Figures

Year	Estimated Global Revenue	Comments
2004-2005	$500 million	Peak sales for Razadyne
2011	$50 million (post-patent expiry)	Sharp decline; generic entry, patent loss
2022	<$10 million	Mostly generics, waning brand presence

What Are the Strategic Opportunities and Challenges?

Opportunities

• Developing a new formulation, delivery method, or combination therapy.
• Targeting unmet needs in early-stage Alzheimer’s or other cognitive impairments.

Challenges

• Competing with highly effective or more innovative drugs.
• Navigating patent expirations and generic price erosion.
• Demonstrating compelling clinical benefits beyond symptomatic relief.

Key Takeaways

• Razadyne’s market share and revenues have declined sharply since patent expiry.
• Competitive pressures from generics and advanced therapeutics limit growth.
• The future of Razadyne relies on innovation within its product class or novel therapeutic approaches for Alzheimer’s.

FAQs

1. Why did Razadyne’s sales decline significantly after patent expiry?
Patent expiry allowed generics to enter the market, drastically reducing prices and sales volume for the branded drug.

2. Are there any ongoing clinical trials for Razadyne?
No public records indicate ongoing development for Razadyne; focus has shifted to other experimental therapies.

3. Can Razadyne be repositioned for other indications?
There are no current approvals or evidence supporting its repositioning outside Alzheimer’s symptom management.

4. What are the main competitors for Razadyne?
Donepezil, rivastigmine, and memantine lead the market, with newer agents like aducanumab and lecanemab emerging as disease-modifying options.

5. What are the prospects for Razadyne’s generic versions?
Generic versions are available, leading to continued sales, but revenue is minimal and declining.

---

Sources:

1. IQVIA, "Global Alzheimer’s Disease Drugs Market," 2022.
2. U.S. FDA, "Razadyne (galantamine) product approval history."
3. Johnson & Johnson, "Older Product Portfolio Review," 2021.
4. MarketWatch, "Alzheimer’s Drug Market Trends," 2023.
5. CDC, "Alzheimer’s Disease Facts and Figures," 2022.